Analyst Upgrades: Pfizer Inc., JPMorgan Chase & Co., and Goldman Sachs Group Inc

Analysts upwardly revised their ratings and price targets on Pfizer Inc. (NYSE:PFE), JPMorgan Chase & Co. (NYSE:JPM), and Goldman Sachs Group Inc (NYSE:GS)

Nov 29, 2016 at 10:02 AM
facebook X logo linkedin


Analysts are weighing in on Dow stocks Pfizer Inc. (NYSE:PFE), JPMorgan Chase & Co. (NYSE:JPM), and Goldman Sachs Group Inc (NYSE:GS). Here's a quick roundup of today's bullish brokerage notes on PFE, JPM, and GS.

  • PFE is up 0.5% this morning at $31.71, following news the Food and Drug Administration (FDA) accepted for priority review the Biologics License Application for Avelumab by EMD Serono Inc., with whom Pfizer has partnered. Barclays is also boosting the stock with an upgrade to "overweight" and a price-target increase to $38 from $37. Pfizer Inc. has cooled on the charts in recent weeks -- which isn't entirely surprising -- and now sits just below its year-to-date breakeven level. Looking to the options arena, call buying has had an edge on an absolute basis, but puts have been more popular than normal relative to what's normally seen. For instance, PFE's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 0.81 ranks above four-fifths of all comparable readings from the past year. 

  • JPM saw its price target raised to $88 from $77 at KBW, representing all-time-high territory, and now the stock is 0.6% higher at $78.77. The shares have been consolidating atop the $78 level in recent weeks, as they look to add to their nearly 20% year-to-date advance. An extended round of bullish attention could help them do just that. Specifically, the majority of brokerage firms covering JPMorgan Chase & Co. still rate it a "hold" or "strong sell," despite its strong showing on the charts this year. 

  • KBW also weighed in bullishly on GS, raising its outlook to "outperform," and upping its price target to $240 from $185. Like its banking peer JPM, Goldman Sachs Group Inc has been fantastic on the charts this year, outperforming the S&P 500 Index (SPX) by 28 percentage points during the past two months alone, and was last seen trading up 0.6% at $210.87 -- just shy of last week's annual high of $213.41. Regardless, short-term options traders are more put-skewed than normal, according to GS' Schaeffer's put/call open interest ratio (SOIR) of 1.25, which sits only 7 percentage points from an annual high. 
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI